Mild stroke: Safety and outcome in patients receiving thrombolysis

Acta Neurologica Scandinavica

Volumn 129, Issue S198, 2014, Pages 37-40

  Logallo, N ^a   Kvistad, C E ^b   Naess, H ^a,b,c   Waje Andreassen, U ^b   Thomassen, L ^a,b  

^a UNIVERSITY OF BERGEN   (Norway)

^b HAUKELAND UNIVERSITY HOSPITAL   (Norway)

^c STAVANGER UNIVERSITY HOSPITAL   (Norway)

Author keywords

Intravenous thrombolysis; Mild stroke; Stroke epidemiology; Stroke outcome

Indexed keywords

ALTEPLASE; FIBRINOLYTIC AGENT; TISSUE PLASMINOGEN ACTIVATOR;

ADULT; AGED; ARTICLE; BLOOD CLOT LYSIS; BRAIN HEMORRHAGE; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; HOSPITAL ADMISSION; HOSPITAL DISCHARGE; HUMAN; MAJOR CLINICAL STUDY; MALE; NATIONAL INSTITUTES OF HEALTH STROKE SCALE; OUTCOME ASSESSMENT; PATIENT SAFETY; RANKIN SCALE; TRANSIENT ISCHEMIC ATTACK; VERY ELDERLY; BRAIN ISCHEMIA; COMPLICATION; FIBRINOLYTIC THERAPY; MIDDLE AGED; STROKE; TIME; TREATMENT OUTCOME;

ADULT; AGED; AGED, 80 AND OVER; BRAIN ISCHEMIA; FEMALE; FIBRINOLYTIC AGENTS; HUMANS; MALE; MIDDLE AGED; STROKE; THROMBOLYTIC THERAPY; TIME FACTORS; TISSUE PLASMINOGEN ACTIVATOR; TREATMENT OUTCOME;

EID: 84895485838     PISSN: 00016314     EISSN: 16000404     Source Type: Journal    
DOI: 10.1111/ane.12235     Document Type: Article

References (23)

1. Adams HP Jr, del Zoppo G, Alberts MJ et al. Guidelines for the early management of adults with ischemic stroke: a guideline from the American Heart Association/American Stroke Association Stroke Council, Clinical Cardiology Council, Cardiovascular Radiology and Intervention Council, and the Atherosclerotic Peripheral Vascular Disease and Quality of Care Outcomes in Research Interdisciplinary Working Groups: The American Academy of Neurology affirms the value of this guideline as an educational tool for neurologists. Circulation 2007;115:e478-534.
2. European Stroke Organisation Executive C, Committee ESOW. Guidelines for management of ischaemic stroke and transient ischaemic attack 2008. Cerebrovasc Dis 2008;25:457-507.
3. Kleindorfer D, Kissela B, Schneider A et al. Eligibility for recombinant tissue plasminogen activator in acute ischemic stroke: a population-based study. Stroke 2004;35:e27-9.
4. California Acute Stroke Pilot Registry Investigators. Prioritizing interventions to improve rates of thrombolysis for ischemic stroke. Neurology 2005;64:654-9.
5. Helsinki Stroke Thrombolysis Registry Group. Intravenous thrombolysis for acute ischemic stroke patients presenting with mild symptoms. Int J Stroke 2013;8:293-9.
6. Nedeltchev K, Schwegler B, Haefeli T et al. Outcome of stroke with mild or rapidly improving symptoms. Stroke 2007;38:2531-5.
7. National Institute of Neurological Disorders Stroke rt PASSG. Recombinant tissue plasminogen activator for minor strokes: the National Institute of Neurological Disorders and Stroke rt-PA Stroke Study experience. Ann Emerg Med 2005;46:243-52.
8. Willey JZ, Khatri P, Khoury JC et al. Variability in the use of intravenous thrombolysis for mild stroke: experience across the SPOTRIAS network. J Stroke Cerebrovasc Dis 2013;22:318-22.
9. Wahlgren N, Ahmed N, Davalos A et al. Thrombolysis with alteplase for acute ischaemic stroke in the Safe Implementation of Thrombolysis in Stroke-Monitoring Study (SITS-MOST): an observational study. Lancet 2007;369:275-82. Epub 2007/01/30. eng.
10. Johnson CJ, Kittner SJ, McCarter RJ et al. Interrater reliability of an etiologic classification of ischemic stroke. Stroke 1995;26:46-51.
11. Easton JD, Saver JL, Albers GW et al. Definition and evaluation of transient ischemic attack: a scientific statement for healthcare professionals from the American Heart Association/American Stroke Association Stroke Council; Council on Cardiovascular Surgery and Anesthesia; Council on Cardiovascular Radiology and Intervention; Council on Cardiovascular Nursing; and the Interdisciplinary Council on Peripheral Vascular Disease. The American Academy of Neurology affirms the value of this statement as an educational tool for neurologists. Stroke 2009;40:2276-93.
12. The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group. Tissue plasminogen activator for acute ischemic stroke. N Engl J Med 1995;333:1581-7.
13. Hacke W, Kaste M, Bluhmki E et al. Thrombolysis with alteplase 3 to 4.5 hours after acute ischemic stroke. N Engl J Med 2008;359:1317-29.
14. Adams HP Jr, Bendixen BH, Kappelle LJ et al. Classification of subtype of acute ischemic stroke. Definitions for use in a multicenter clinical trial. TOAST. Trial of Org 10172 in Acute Stroke Treatment. Stroke 1993;24:35-41. Epub 1993/01/01. eng.
15. Thomassen L, Waje-Andreassen U, Broegger J, Naess H. Acute stroke centre - the changing focus of stroke unit care. The Bergen NORSTROKE Study. Acta Neurol Scand 2012;125:410-5.
16. Kvistad CE, Logallo N, Thomassen L, Waje-Andreassen U, Brogger J, Naess H. Safety of off-label stroke treatment with tissue plasminogen activator. Acta Neurol Scand 2013;128:48-53.
17. Group ISTc, Sandercock P, Wardlaw JM, et al. The benefits and harms of intravenous thrombolysis with recombinant tissue plasminogen activator within 6 h of acute ischaemic stroke (the third international stroke trial [IST-3]): a randomised controlled trial. Lancet 2012;379:2352-63.
18. Khatri P, Kleindorfer DO, Yeatts SD et al. Strokes with minor symptoms: an exploratory analysis of the National Institute of Neurological Disorders and Stroke recombinant tissue plasminogen activator trials. Stroke 2010;41:2581-6.
19. Urra X, Arino H, Llull L et al. The outcome of patients with mild stroke improves after treatment with systemic thrombolysis. PLoS ONE 2013;8:e59420.
20. Memis S, Tugrul E, Evci ED, Ergin F. Multiple causes for delay in arrival at hospital in acute stroke patients in Aydin, Turkey. BMC Neurol 2008;8:15.
21. Baumann CR, Baumgartner RW, Gandjour J, von Budingen HC, Siegel AM, Georgiadis D. Good outcomes in ischemic stroke patients treated with intravenous thrombolysis despite regressing neurological symptoms. Stroke 2006;37:1332-3.
22. Khatri P, Conaway MR, Johnston KC, Acute Stroke Accurate Prediction Study Investigators. Ninety-day outcome rates of a prospective cohort of consecutive patients with mild ischemic stroke. Stroke 2012;43:560-2.
23. Hassan AE, Hassanzadeh B, Tohidi V, Kirmani JF. Very mild stroke patients benefit from intravenous tissue plasminogen activator without increase of intracranial hemorrhage. South Med J 2010;103:398-402.